Neuralink & Brain-Computer Interfaces

On 29-30 October 2026 Elon Musk posted on X that Blindsight, Neuralink's second product, is 'ready from an engineering standpoint' and waiting on regulatory approval (reported by Tesla North, 29 Oct 2026). The FDA granted Blindsight Breakthrough Device Designation in September 2024. No approval has been reported, and no patient count for Blindsight was given. This is a company statement, not an independent result.

Per Musk's early-October 2026 comments as relayed by Tesla North (29 Oct 2026), Neuralink pretrained neural encoders on more than 50,000 hours of brain data from clinical trial participants, which he said cut calibration time. The same source cites one ALS participant reaching 75 words per minute in the first week of speech-restoration work. Both are unaudited company claims.

Press coverage (Pulse, 14 Apr 2026) described Neuralink shifting toward speech-focused trials, with results expected later in 2026. A speech-trial start had been announced for October 2025 and carries FDA Breakthrough designation. This matches the deck's signpost that speech decoding is the next big prize.

• Fierce Biotech (6 Nov 2025): Series D led by Double Point Ventures, with Arch Ventures, Khosta Ventures, Bezos Expeditions, NTI and Metis.
• Stated use: expand operations and accelerate commercialisation of its endovascular BCI for people with paralysis.
• Company said the device had been implanted in 10 patients across US and Australian trials at that point.
• MassDevice reported the round brings total funding to about $345M (search summary only, not independently confirmed).

Multiple outlets reported a $600-650M raise in mid-2025 at roughly a $9B valuation (Semafor, May 2025, and others). Reports of a 2026 round at a higher valuation conflict with each other and could not be verified, so the deck's figure stands.

Not refreshed: Neuralink's current implant count (reports range from about 12 to 20+; the deck's 21 by early 2026 could not be confirmed or updated), cumulative hours of use, Precision Neuroscience and Blackrock funding, China BCI funding, and the BCI market-size forecasts (one source gives about $5.2B for 2026, which conflicts with the deck's Grand View Research series and was not adopted).

Your brain runs on electricity: 86 billion neurons firing in patterns. A BCI listens to those signals and decodes what you intend. It doesn't read 'thoughts' in any literary sense; it reads the electrical intent to move, type or speak.

1. Intend: you think about moving a cursor or hand.
2. Fire: neurons in your motor cortex fire in a pattern.
3. Record: electrodes pick up those electrical signals.
4. Decode & act: AI translates the pattern into a command, and the cursor moves.

1. EEG cap: wearable, low signal (non-invasive)
2. Endovascular: via blood vessels
3. Surface array: on the brain
4. Penetrating: into the cortex (fully implanted)

Neuralink's bet is bandwidth: go into the cortex with ultra-thin threads and a robot surgeon, and read far more neurons than anyone else. A coin-sized implant, threads thinner than a hair, inserted by a purpose-built robot.

A human hair is ~80 microns; a Neuralink thread is ~5. That thinness and flexibility let it move WITH the brain instead of tearing it, the breakthrough that makes long-term recording possible.

1. Threads: 64 flexible threads, thinner than hair, hold 1,024 electrodes.
2. Robot: a surgical robot inserts them, avoiding blood vessels.
3. Chip: a coin-sized implant reads and digitises the signals.
4. Wireless: decoded intent streams to a computer or phone.

The first Neuralink patients are people with paralysis, and they are already browsing, gaming and controlling robotic arms with their minds. For someone who cannot move, regaining digital control of the world is transformative.

1. 2016Founded: Neuralink starts
2. 2023FDA nod: cleared for human trials
3. 2024First human: cursor control by thought
4. 2025Robotic arm: 13 implants, 15,000+ hours
5. 2026Scaling: 21 patients, automated surgery

Patients now type by thought faster than ever demonstrated. Neuralink participants have set records for cursor-and-type speed via a BCI, approaching practical, everyday usability. For an ALS patient losing speech, that is the difference between silence and voice.

There is no agreed 'right way' to build a BCI: the field is split between three fundamentally different bets on invasiveness. More signal versus less risk: the entire industry is arguing about where to draw that line.

Mapped on invasiveness (x-axis) against bandwidth/capability (y-axis): Neuralink sits top-right (the frontier), with Blackrock and Precision just below it; Synchron sits lower-left; EEG wearables sit at the bottom-left (low capability, safe). The corners are labelled high-capability and safe (top-left), frontier (top-right), low-capability and safe (bottom-left), and invasive but limited (bottom-right).

That figure rests entirely on therapy (paralysis, ALS, stroke, blindness), not on enhancement. The real, investable opportunity is medicine; the sci-fi is a free option nobody should pay for.

The deepest question isn't technical: once a machine can read and write to your brain, whose thoughts are they? No prior technology has forced that question. BCIs make it urgent, and soon.

• Consent: can a desperate patient truly weigh brain surgery for a chance at control?
• Ownership: who owns your neural data: you, the company, or a cloud server?
• Access: will therapy be universal, or enhancement a luxury for the wealthy?
• Autonomy: if a device quietly shapes your choices, are they still yours?

1. Do trials scale safely? Patient numbers and complication rates.
2. Does longevity hold up? Implants must work for years, not months.
3. Who reaches approval first? The safest design may win the market.
4. Does speech decoding land? Restoring voice is the next big prize.
5. Does regulation keep pace? Neural data needs rules before it scales.

The astonishing part isn't the science-fiction dream of merging with machines. It's the quiet reality that a person who cannot move can now, with a thought, move a cursor, and reclaim a piece of their life.

• Neuralink: clinical updates, PRIME study, device specifications (2024-26).
• Synchron: endovascular BCI disclosures and trials.
• Precision Neuroscience: Layer 7 array, FDA clearance (2025).
• Blackrock Neurotech: decades of human BCI implants.
• McKinsey: medical BCI market forecast to 2040.
• Grand View Research: brain-computer interface market size.
• ClinicalTrials.gov: BCI trial registrations and enrolment data.
• Figures marked 'estimate' or 'target' are compilations; the field moves fast.